CorrectSequence posts CS-206 15-month data

CorrectSequence Therapeutics said on June 2 that its sickle cell disease therapy CS-206 had kept the first patient treated in China free of vaso-occlusive crises for more than 15 months after engraftment. The Shanghai-based company said the patient, a 21-year-old woman from Nigeria, also remained free of anemia for 13 consecutive months after her last red-cell transfusion. The update came in a company press release and study summary, not in a peer-reviewed journal article. That matters because the readout is detailed enough to show what the company is highlighting, but still needs to be read as company-reported clinical data. ### What exactly did CorrectSequence report? CorrectSequence said the patient achieved the study’s primary efficacy endpoint by remaining free of both vaso-occlusive crises, or VOCs, and anemia after treatment. In the company’s wording, the patient was VOC-free for more than 15 months following engraftment and free of VOCs and anemia for 13 straight months starting 60 days after the last red-cell transfusion. (prnewswire.com) The June 2 release also said the patient received CS-206 in February 2025. The Chinese-language company website gave a specific date, saying the infusion took place on February 14, 2025, and that the last transfusion occurred 11 days later. ### What changed in the patient’s blood counts and hemoglobin profile? (prnewswire.com) CorrectSequence said neutrophil engraftment was observed on Day 13 after treatment and platelet counts exceeded 50×10^9/L on Day 21. Those are the company’s markers for hematopoietic recovery after the edited cells were returned. (prnewswire.com) Within one month, the company said fetal hemoglobin, or HbF, rose significantly and continuously while sickle hemoglobin, or HbS, fell substantially and persistently. By Month 3, the HbF-to-HbS ratio had stabilized at about 6:4 and remained stable, according to the release. The company also said the therapy reduced hemolysis, the breakdown of red blood cells that contributes to anemia and other complications in sickle cell disease. (prnewswire.com) ### How is CS-206 supposed to work? CS-206 is an autologous hematopoietic stem-cell therapy built around what CorrectSequence calls transformer Base Editing, or tBE. The company said it edits the HBG1/2 promoter region in a patient’s own stem cells to mimic naturally occurring beneficial mutations that reactivate gamma-globin expression and raise fetal hemoglobin. (prnewswire.com) CorrectSequence said that increase in fetal hemoglobin is intended to suppress red blood cell sickling and reduce VOCs and hemolysis. The company contrasted the approach with CRISPR-based editing that creates DNA double-strand breaks, saying CS-206 performs precise single-base changes instead. That comparison is the company’s characterization of the platform and safety rationale. (prnewswire.com) ### What did the company say about safety? The June 2 release said no product-related adverse events had been observed to date in the treated patient. CorrectSequence described the follow-up data as showing favorable safety and efficacy. One limitation is that the update appears to cover a single named clinical case in the public materials now available. (prnewswire.com) The release does not, in the lines available, provide a broader enrolled-patient count for CS-206 or comparative data against another therapy. ### How should readers place this result? The June 2 report is best read as an early clinical proof point for one patient rather than a definitive trial result. The data are notable because they combine a long follow-up window, no reported product-related adverse events, and sustained changes in hemoglobin measures tied to sickle cell biology. But the evidence disclosed publicly so far is still company-reported and limited in scope. (prnewswire.com) CorrectSequence’s next public marker on CS-206 will be additional follow-up or broader patient data, if the company discloses them. For now, the primary source remains the June 2, 2026 press release and study summary posted by CorrectSequence and distributed by PR Newswire. (prnewswire.com)